← All trials
NCT04711603
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 16, 2021
- Primary completion
- Jan 31, 2023
- Completion date
- Jan 31, 2023
- First posted
- Jan 15, 2021
- Last posted
- Aug 27, 2021
- Enrollment
- 172
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kissei PharmaceuticalsLead sponsor
- Kissei PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.